90924-41-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Cyano-3-(4-hydroxyphenyl)propanoic acid is used as an intermediate in the production of L-dopa, a medication for treating Parkinson's disease. Its role in the biosynthetic pathway of neurotransmitters makes it a valuable component in the development of treatments for neurological disorders.
Used in Biotechnological Industry:
4-HPPA is used as a key component in the biosynthetic pathway of neurotransmitters, such as dopamine and norepinephrine, making it a potential candidate for applications in the biotechnological industry. Its antioxidant properties also contribute to its potential use in the development of novel therapeutic agents and biotechnological applications.
Used in Antioxidant Applications:
2-Cyano-3-(4-hydroxyphenyl)propanoic acid is used as an antioxidant due to its ability to neutralize free radicals and protect cells from oxidative damage. This property makes it a valuable compound for use in the development of antioxidants and other health-related products.

Upstream product

• 122520-77-8 (E)-2-cyano-3-(4-hydroxyphenyl)prop-2-enoic acid 
• 28166-41-8 α-cyano-4-hydroxycinnamic acid 

Downstream Products

• 343880-36-4 methyl 2-cyano-3-(4-hydroxyphenyl)propanoate 
• 1356599-92-2 methyl 2-cyano-3-{4-[(3-hydroxybenzyl)oxy]phenyl}propanoate 
• 1356599-93-3 methyl 2-cyano-3-{4-[(3-{[(2E,2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}propanoate 
• 1356598-64-5 2-cyano-3-{4-[(3-{[(2E,2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}propanoic acid 

Relevant academic research and scientific papers

The organic-synthetic potential of recombinant Ene reductases: Substrate-Scope Evaluation and Process Optimization

In this study an evaluation of the synthetic potential of a broad range of recombinant ene reductases was performed. In detail, a library of 23 ene reductases was used to screen the C=C reduction of 21 activated alkenes from different compound classes as substrates. The chosen set of substrates comprises nitroalkenes with an aryl substituent at the β-position and a methyl substituent at the α- or β-position, α,β-unsaturated carboxylic acids and their esters with and without substituents at the β-position, a range of cyclic α,β-unsaturated ketones with different ring sizes and substitution patterns and one α,β-unsaturated boronic acid. After we obtained insight into the substrate scope, several biotransformations were prioritised and further investigated in a screening of 41 reaction parameters (which included chaotropic and kosmotropic salts, polyols, buffer solutions, amino acids and organic solvents) towards their impact on the activity and enantioselectivity of the applied ene reductases. Under the optimised conditions, selected reduction processes were performed on an increased lab scale (up to 30 mL) with up to 10% substrate concentration, which led in general to both high conversion and (if chiral products were formed) enantioselectivity. Comprehensive screening: A detailed screening of 23 recombinant ene reductases for the reduction of 21 activated alkenes is performed as well as a subsequent study of the influence of 41 reaction parameters towards the enzyme activity and selectivity of selected reactions. In addition, a range of biocatalytic reductions on an increased laboratory scale are performed with substrate concentrations between 5 and 100 gL-1. EWG=Electron-withdrawing group.

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

Catalytic transfer hydrogenation and hydrogenolysis in ionic liquids with Pd/MgLa mixed oxide and Pd/MgAl hydrotalcite as recyclable catalysts

A new Pd/MgLa mixed oxide and the known Pd/MgAl hydrotalcite catalysts were applied and recycled successfully in catalytic transfer hydrogenation reactions in ionic liquids. Some α,β-unsaturated carboxylic acid derivatives were hydrogenated in excellent yields. The catalysts were recycled without significant loss of activity. Besides that, a number of halogenated aromatic compounds were dehalogenated under similar catalytic transfer conditions. Copyright Taylor & Francis Group, LLC.